Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
World J Surg Oncol. 2024 Nov 28;22(1):318. doi: 10.1186/s12957-024-03598-w.
PMP is a rare clinical syndrome characterized by the accumulation of mucinous material in the peritoneal cavity. The combination of CRS and HIPEC is the standard treatment, known to improve survival outcomes. However, follow-up adherence is critical for early detection of recurrence and extending survival. This study is the first to specifically investigate postoperative follow-up adherence in PMP patients treated with CRS and HIPEC.
To explore the socio-demographic and clinical determinants of follow-up adherence and its impact on survival in PMP patients treated with CRS and HIPEC.
This single-center, six-year retrospective study included 111 PMP patients who underwent CRS and HIPEC. Patients were categorized into compliant (control) and non-compliant (study) groups. Follow-up was initiated by the physician, with patients returning for regular visits as recommended. Kaplan-Meier analysis was used to evaluate survival outcomes, while univariate analysis identified factors influencing follow-up adherence.
Among 111 patients, 32 died by August 2024, with 1-, 3-, and 5-year survival rates of 88%, 66%, and 53%, respectively. High PCI scores (P < 0.001) and poorer histopathological types (P = 0.002) were significant predictors of reduced survival. Non-compliance with follow-up showed a trend toward decreased survival (P = 0.07). Significant risk factors for non-compliance included lower ASA scores (P = 0.020), middle- and low-income levels (P = 0.034), and parental survival status (P = 0.003). Middle- and low-income patients also experienced longer delays in seeking medical advice and had fewer cases detected through routine health screenings (P = 0.019).
Follow-up compliance has a potential impact on survival outcomes in PMP patients treated with CRS and HIPEC. Socio-demographic factors significantly influence adherence, highlighting the need for tailored interventions to enhance patient management.
PMP 是一种罕见的临床综合征,其特征是腹腔内积聚粘蛋白物质。CRS 和 HIPEC 的联合应用是标准治疗方法,已知可以改善生存结果。然而,随访依从性对于早期发现复发和延长生存至关重要。本研究是首次专门研究接受 CRS 和 HIPEC 治疗的 PMP 患者的术后随访依从性。
探讨影响接受 CRS 和 HIPEC 治疗的 PMP 患者随访依从性及其对生存的影响的社会人口学和临床决定因素。
这是一项单中心、六年回顾性研究,纳入了 111 例接受 CRS 和 HIPEC 治疗的 PMP 患者。患者分为依从性(对照组)和不依从性(研究组)两组。随访由医生启动,患者按照建议定期就诊。采用 Kaplan-Meier 分析评估生存结果,单因素分析确定影响随访依从性的因素。
在 111 例患者中,截至 2024 年 8 月,有 32 例死亡,1、3 和 5 年生存率分别为 88%、66%和 53%。较高的 PCI 评分(P<0.001)和较差的组织病理学类型(P=0.002)是生存降低的显著预测因素。不遵守随访也显示出降低生存的趋势(P=0.07)。不遵守随访的显著危险因素包括较低的 ASA 评分(P=0.020)、中低收入水平(P=0.034)和父母的生存状况(P=0.003)。中低收入患者也经历了更长的就医延迟,并且通过常规健康筛查发现的病例更少(P=0.019)。
在接受 CRS 和 HIPEC 治疗的 PMP 患者中,随访依从性对生存结果有潜在影响。社会人口学因素对依从性有显著影响,这突出表明需要采取针对性干预措施来加强患者管理。